Form4insider filings, from the source

SEC Form 4 · accession 0001144204-15-027775

INTERCEPT PHARMACEUTICALS, INC. · ICPT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Mark Pruzanski
Officer — CEO & President · Director
Period of report
May 1, 2015
Accepted (ET)
May 5, 2015 · 9:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockMay 1, 2015M12,500$8.6667A508,243D
Common StockF3May 1, 2015S1,700$251.3932D506,543D
Common StockF4May 1, 2015S3,350$252.5309D503,193D
Common StockF5May 1, 2015S4,338$253.5248D498,855D
Common StockF6May 1, 2015S1,539$254.6334D497,316D
Common StockF7May 1, 2015S661$255.4933D496,655D
Common StockF8May 1, 2015S200$256.415D496,455D
Common StockF9May 1, 2015S400$258.50D496,055D
Common StockF10May 1, 2015S312$259.3342D495,743D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Options to Purchase Common StockF2$8.6667May 1, 2015M12,500D—Aug 16, 2020Common Stock12,500134,128D

Explanation of responses